On January 27, 2021 GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the "Company"), reported that technical corrections were made to the voting results of the holders of the convertible bonds issued by the Company on October 16, 2017 (the "OCEANEs") at the Bondholders Meeting which took place on January 25, 2021 (the "Bondholders Meeting") (Press release, Genfit, JAN 27, 2021, https://ir.genfit.com/news-releases/news-release-details/genfit-technical-corrections-results-january-25-2021-bondholders [SID1234574341]). These corrections have no impact on the fact that all of the resolutions by the Bondholders Meeting were approved, and are the result of corrections made by BNP Paribas Securities Services, the external provider in charge of centralizing the Bondholders Meeting votes. They are not the result of any action or responsibility of the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Bondholders Meeting quorum remains unchanged (70.88%) and the settlement operations for the partial buyback of the 2,895,260 OCEANEs that certain bondholders have agreed to sell to the Company will take place as planned by January 29, 2021.